Patrick Craven

[Patrick Craven @Pat_Craven]

@StephanieKelton , was just exposed to your theory and I’m captivated. Just bought your book. Curious how not having US as a reserve currency impacts your theory? Is bitcoin a solution, or not? Thank for pioneering new ideas.

[Hannah Calkins, PhD @hannah_calkins]

Check out this podcast episode I was a guest on with @MercyOne_Iowa to learn about circulating tumor DNA and how @NateraGenetics is utilizing ctDNA to improve the management of cancer patient care through our molecular residual disease assay, Signatera!! https://t.co/Z8ylzjmtm8

[Patrick Craven @Pat_Craven]

@WMPhoenixOpen @tpcscottsdale @Taylor_Morrison @WasteManagement @adamk2d let’s go!

[Kellischultz1 @kellischultz1]

Exciting news! Welcome Dr. Liu!
Natera Appoints Minetta Liu, M.D. as Chief Medical Officer of Oncology https://t.co/JrhMjhC8kM

[Natera Oncology @NateraOncology]

For Jeffrey, who is living with metastatic #melanoma, @NateraGenetics's Signatera test helped him and his oncologist monitor immunotherapy treatment.

Click the link to watch his story to learn more about his experience 👉 https://t.co/llRtiJXRez

#SkinCancerAwarenessMonth

[Kellischultz1 @kellischultz1]

With CT contrast scans being actively restricted in many hospital systems, please contact me to learn more about how #ctdna Signatera can help as a surveillance tool!

[Patrick Craven @Pat_Craven]

Latest findings from CIRCULATE-Japan shared at ASCO #GI22. More than 3,000 #ColorectalCancer patients are enrolled in this study, which is the largest prospective, multi-center, MRD-guided trial in CRC, using Signatera to monitor #MRD status. https://t.co/ynnyEkTQD9

[Natera Oncology @NateraOncology]

Though ASCO GI may be over, the excitement is still here!

Read about new data presented that shows Signatera's ability to predict #colorectalcancer relapse 8 months before radiological detection of recurrence: https://t.co/chfFzHEKLN

#GI21 #CRCSM @CBankheadMPT @TennaVesterman

[Natera Oncology @NateraOncology]

Big news! Draft LCD from #Medicare was issued to use #Signatera for #immunotherapy response monitoring in solid tumors. We're thrilled to be able to serve this broad set of patients who may benefit from MRD testing. https://t.co/r0HphgOMzd

[Natera Oncology @NateraOncology]

🆕 Signatera is now covered by Medicare in stages II-III #colorectalcancer! Huge win for cancer patients and providers - expanding access to this new technology will help guide cancer care.

Read our press release here: https://t.co/TFgKNBCzlv

#ctDNA #SignateraLooksDeeper

[Alexey Aleshin @aaleshin]

Excited to announce the finalization of CMS coverage for MRD testing for the millions of early stage CRC patients. This marks a new era in the personalization of management of early stage colorectal cancer. #ctDNA #MRD #Signatera

https://t.co/uHXiliQsQ0

[Pashtoon Kasi MD, MS @pashtoonkasi]

#ASCO20 Virtually every talk @ASCO is about #ctDNA. #LiquidBiopsies are revolutionizing cancer care. 🩸🧬

[Natera Oncology @NateraOncology]

A newly published case study shows how surveillance with Signatera technology can help guide optimal patient care. #MRDtest #esophagealcancer #ctDNA #Signatera @eirinipec @davidjeinstein @aaleshin @smoshkev @DanaFarber @JCOPO_ASCO @ASCO_pubs https://t.co/mGI5IcKR5C

[Helomics @Helomics_]

Today Precision Therapeutics announces its transformation into Helomics Corporation. Read the release: http://t.co/AJO3nmIUcK

[Helomics @Helomics_]

How does ChemoFx work & how can it help doctors make better treatment decisions for #cancer patients? Watch & learn: http://t.co/R5E5QtT0VC

[Helomics @Helomics_]

Manuscript Demonstrating ChemoFx is a Predictive Marker in #OvarianCancer Published by the British Journal of Cancer: http://t.co/msGZDCRMHW

[Patrick Craven @Pat_Craven]

@ChrisMVogel I hate you for this tweet. Delta is Satan.

[Patrick Craven @Pat_Craven]

@MonroeEd nice

[Patrick Craven @Pat_Craven]

@MonroeEd what a great song. Zach Brown Band will be providing me with the weekend anthem.